Roche signs $64m hormone disorder deal with Chiasma
Roche has entered into an agreement with a privately held biopharmaceutical company, Chiasma, to develop and commercialize Chiasma’s proprietary oral product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors.
The global pharma company has paid Chiasma an upfront sum of US $64 million and there are future considerations in place of up to $530 million in development and commercial milestones, as well as tiered, double digit royalties on Octreolin net sales.
“We are especially pleased to have entered into this agreement with Roche, an ideal collaboration partner that has the right development and commercial resources in the areas of endocrinology and oncology to support Octreolin.”
Fredric D. Price, Chiasma’s Chairman and Chief Executive Officer.
Octreolin (Oral Octreotide) is currently being evaluated in a key phase 3 clinical trial for acromegaly.
Under terms of the agreement, Roche has received a worldwide exclusive license to Octreolin and will assume responsibility for the commercialization of the oral product. Chiasma will continue development of the drug through to the competition of these late-stage clinical trials.
“If approved, Octreolin would be an important alternative for patients with acromegaly, a disorder that develops when a person’s pituitary gland produces too much growth hormone. Octreolin is an investigational oral regimen that avoids the painful injections of current treatment options.”
Hal Barron, M.D., Global Head of Product Development and Chief Medical Officer at Roche.
After US FDA approval, the marketing of the drug will be passed over to Roche’s subsidiary, Genentech.
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.